Phathom Pharmaceuticals, Inc. 8-K

What Happened

• On January 7, 2026, Phathom Pharmaceuticals, Inc. (PHAT) filed a Form 8‑K (Item 2.02) to announce that it issued a press release containing preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2025.
• The press release is attached to the filing as Exhibit 99.1 and the filing includes an Inline XBRL cover page (Exhibit 104). The 8‑K itself does not include audited financial statements.

Key Details

• Filing date: January 7, 2026 (Form 8‑K, Item 2.02).
• Period reported: Fourth quarter and full year ended December 31, 2025.
• Material provided: Preliminary, unaudited financial results announced via press release (Exhibit 99.1).
• The Form 8‑K did not include audited financial statements or specific financial figures within the filing text.

Why It Matters

• Preliminary quarterly and year‑end results can affect investor expectations about revenue, profitability and cash flow ahead of audited filings (10‑K/10‑Q).
• Investors should read the attached press release (Exhibit 99.1) for the detailed figures and monitor subsequent SEC filings for audited results and management commentary.
• Because the numbers are preliminary and unaudited, they may be revised when the company files its audited financial statements.